Overview

A Phase 3 Clinical Study to Evaluate Lemzoparlimab for Injection in Combination With Azacitidine (AZA) Versus AZA Monotherapy in Treatment-naïve Patients With Higher-risk Myelodysplastic Syndrome (MDS)

Status:
Not yet recruiting

Trial end date:
2027-03-31

Target enrollment:

Participant gender:

Summary

This phase3 study is a randomized, controlled, open-label, multicenter study to evaluate the efficacy and safety of Lemzoparlimab for injection in combination with AZA versus AZA monotherapy as first-line therapy in treatment-naïve subjects with intermediate- and high-risk MDS.

Phase:

Phase 3

Details

Lead Sponsor:

I-Mab Biopharma Co. Ltd.

Treatments:

Azacitidine